Anzeige
Erschienen in:
17.06.2022 | Review Article
Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis
Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2022
Einloggen, um Zugang zu erhaltenAbstract
Background
Research on semaglutide’s effect on weight loss has been largely focused on Type 2 Diabetics. No meta-analyses of semaglutide’s efficacy in non-diabetic individuals have been conducted to date. Expanding the knowledge of semaglutide’s outcome in non-diabetics may provide impactful changes at the clinical level.
Aim
This systematic review and meta-analysis quantified the efficacy of subcutaneous semaglutide in treating obesity in non-diabetic adult patients compared to placebo.
Method
Academic Search Premier, Cumulative Index to Nursing and Allied Health Literature (CINAHL) complete, MEDLINE with Full Text, Cochrane Central Register of Controlled Trials, medrxiv.org, and clinicaltrials.gov were systematically investigated using a predetermined search strategy from inception to August 21, 2021. Covidence.org was used to screen, select, and extract data by two independent reviewers. Individual study bias was assessed using the Cochrane Risk of Bias 2 tool. Data were exported to RevMan v5.4, where meta-analysis was conducted using a DerSimonian and Laird random-effects model.
Results
The initial search identified 332 relevant articles and ultimately retained four randomized controlled trials encompassing 2,882 participants with a BMI ≥ 27 kg/m2. Patients treated with semaglutide experienced a clinically significant reduction in mean body weight − 11.62 kg (95% CI: -13.03 to -10.21; P < 0.00001).
Conclusion
This systematic review and meta-analysis validates the clinical efficacy of semaglutide for the treatment of obesity in the adult, non-diabetic population.
